Obesity, Thrombotic Risk, and Inflammation in Cancer
- ,
- Luz-Ma-Adriana Balderas-Peña,
- ,
- María G. Zavala-Cerna,
- Carlos Riebeling-Navarro,
- Pedro A. Reyes
- Universidad de Guadalajara,
- ,
- Universidad Autonoma de Guadalajara,
- Unidad de Investigación en Epidemiología Clínica, UMAE, Hospital de Pediatría CMNS-XXI, IMSS/UNAM,
- Instituto Nacional de Cardiologia Ignacio Chavez
Sustainable Development Goals
- SDG 3 Good Health and Well
Publication metrics
Metrics
Abstract
Neoplasms exhibits a high incidence and mortality rates due to their complex and commonly overlapping clinical, biochemical, and morphologic profiles influenced by acquired or inherited molecular abnormalities, cell of origin, and level of differentiation. Obesity appears related to ~ 20% of cancers including endometrial, esophageal, colorectal, postmenopausal breast, prostate, and renal. Several factors other than obesity, i.e., insulin, insulin-like growth factor, sexual hormones, and adipokines may play a potential role in neoplasia. Cancer-associated hypercoagulable and thrombotic states are influenced by abnormalities in the vascular wall and susceptibility to invasion, interference in blood flow and increase in circulating tissue factor and thrombin, activation of cell growth factors, the presence of a central catheter, chemotherapies, neoplasm type, and surgery. In cancer, thromboembolic complications are the second most frequent cause of death with pulmonary thromboembolism in ~ 50% of cases postmortem. Thrombosis worsens prognosis as demonstrated with a survival rate as low as 12% per year vs 36% in nonthrombic patients. Deep vein thrombosis is the most frequent thromboembolic complication in cancer. It is usually detected at diagnosis and within the first 3 months of chemotherapy. The underlining mechanisms of this association should be further studied to identify patients at higher risk and develop adequate prevention, diagnostic, and treatment measures. The D-dimer test can be successfully used to assess the fibrinolytic phase of coagulation and as such is routinely used in suspected cases of deep vein thrombosis and pulmonary thromboembolism. In addition, significant advances have been made in understanding the composition and functional capabilities of the gut microbiota in the inflammatory process, obesity, and its roles in cancer; however, the intricate balance that exists within the microbiota may not only affect the host directly, it can also disrupt the entire microbial community. Conclusions: Cancer is a prothrombotic and inflammatory state in which the activation of coagulation is related to tumor growth, angiogenesis, and metastasis. It is important to identify the relationship between body mass index with these processes and clarify their importance in cancer prognosis. Future research should answer the question if manipulation of resident microbial communities could potentially improve prognosis and treatment outcome.
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 71-89 (19 pages)Publication milestones
- Published - 2018
Publication status
Volume
85Publication series
- Publication series name: Advances in Clinical Chemistry
ISSN (Print): 0065-2423
Volume: 85
ISBN (Print)
9780128152058Publication IDs
- Scopus: 85042875687
- WOS: 000436593600004
Host publication title
Advances in Clinical ChemistryHost publication editors
- Gregory S. Makowski
